Zogenix, Inc. (NASDAQ:ZGNX) Director Roger Hawley sold 11,797 shares of the business’s stock in a transaction dated Friday, December 8th. The stock was sold at an average price of $37.02, for a total value of $436,724.94. Following the transaction, the director now directly owns 105,575 shares of the company’s stock, valued at approximately $3,908,386.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Roger Hawley also recently made the following trade(s):

  • On Monday, December 11th, Roger Hawley sold 63,203 shares of Zogenix stock. The stock was sold at an average price of $36.84, for a total value of $2,328,398.52.

Shares of Zogenix, Inc. (NASDAQ:ZGNX) traded up $0.35 during mid-day trading on Monday, reaching $37.05. The company’s stock had a trading volume of 632,811 shares, compared to its average volume of 670,900. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.23. Zogenix, Inc. has a 12-month low of $7.70 and a 12-month high of $42.60.

Several brokerages have recently commented on ZGNX. Mizuho reissued a “buy” rating and set a $51.00 price objective on shares of Zogenix in a report on Thursday. BidaskClub raised Zogenix from a “sell” rating to a “hold” rating in a research note on Friday, August 18th. ValuEngine raised Zogenix from a “sell” rating to a “hold” rating in a research note on Saturday, September 30th. JMP Securities began coverage on Zogenix in a research note on Monday, November 27th. They issued an “outperform” rating and a $56.00 target price for the company. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $50.00 target price (up previously from $20.00) on shares of Zogenix in a research note on Monday, October 2nd. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $42.67.

A number of hedge funds have recently made changes to their positions in ZGNX. VHCP Management II LLC bought a new stake in Zogenix in the third quarter valued at approximately $31,792,000. JPMorgan Chase & Co. raised its holdings in shares of Zogenix by 1,794.4% during the second quarter. JPMorgan Chase & Co. now owns 286,299 shares of the company’s stock valued at $4,152,000 after acquiring an additional 271,186 shares in the last quarter. Broadfin Capital LLC bought a new position in shares of Zogenix during the second quarter valued at approximately $3,806,000. Perceptive Advisors LLC raised its holdings in shares of Zogenix by 6.4% during the third quarter. Perceptive Advisors LLC now owns 3,670,357 shares of the company’s stock valued at $128,646,000 after acquiring an additional 222,055 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Zogenix by 89.4% during the first quarter. Dimensional Fund Advisors LP now owns 410,641 shares of the company’s stock valued at $4,455,000 after acquiring an additional 193,827 shares in the last quarter. Hedge funds and other institutional investors own 73.43% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/11/zogenix-inc-zgnx-director-sells-436724-94-in-stock.html.

About Zogenix

Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.

Receive News & Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.